Work

156P Liver metastases correlate with shortened survival and increased dissociate response in patients treated with T cell engagers

Year: 2024

Type: article

Abstract: Highest grade CRS per subject.Conclusions: There were no major differences in safety outcomes following tarlatamab administration with 6-8 h outpatient versus 48 h inpatient monitoring in cycle 1.Clinical trial identification: NCT03319940.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2024.100785

Authors: N. Herbel, C. Helal, R. Sun, S. Ammari, K. Ouali, F-X. Danlos, V. Goldschmidt, A. Mouren, A. Gazzah, R. Bahleda, A. Hollebecque, C. Henon, S. Postel-Vinay, Y. Loriot, A. Marabelle, S. Champiat, C.P. Massard, C. Baldini, M. Roulleaux Dugage

Institutions: Institut Gustave Roussy, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,170

OpenAlex ID: W4405375147

FWCI:

Cites:

Cited by:

Related to: 10